Researchers are excited about the medication , a novel dual agonist showing significant outcomes in early trials for size loss . It functions by impacting both pathways : GLP-1 and GIP, that , when stimulated, assist regulate cravings and boost calorie burn. Early observations demonstrate considerable size loss and possible improvements for people